Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

Andrea Eisen, Jan Lubinski, Jacek Gronwald, Pal Moller, Henry T. Lynch, Jan Klijn, Charmaine Kim-Sing, Susan L. Neuhausen, Lucy Gilbert, Parviz Ghadirian, Siranoush Manoukian, Gad Rennert, Eitan Friedman, Claudine Isaacs, Eliot Rosen, Barry Rosen, Mary Daly, Ping Sun, Steven A. Narod, Olufunmilayo OlopadeShelly Cummings, Nadine Tung, Fergus Couch, William D. Foulkes, Susan Domchek, Dominique Stoppa-Lyonnet, Ruth Gershoni-Baruch, David Horsman, Teresa Wagner, Howard Saal, Ellen Warner, Wendy Meschino, Kenneth Offit, Amber Trivedi, Mark Robson, Michael Osborne, Dawna Gilchrist, Charis Eng, Jeffrey Weitzel, Wendy McKinnon, Marie Wood, Christine Maugard, Barbara Pasini, Peter Ainsworth, Kevin Sweet, Boris Pasche, Taya Fallen, Beth Karlan, Raluca N. Kurz, Susan Armel, Anna Tulman, Edmond Lemire, Jane Mclennan, Gareth Evans, Tomas Byrski, Tomas Huzarski, Lee Shulman

Research output: Contribution to journalArticlepeer-review

147 Scopus citations


Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.

Original languageEnglish (US)
Pages (from-to)1361-1367
Number of pages7
JournalJournal of the National Cancer Institute
Issue number19
StatePublished - Oct 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers'. Together they form a unique fingerprint.

Cite this